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The Carotid Revascularization Endarterectomy vs. Stenting Trial (CREST) completed randomization on July 18, 2008.
Sponsored by the National Institute of Neurological Disorders and Stroke (NINDS), the trial has enrolled 2,522
participants across North America and is the largest randomized clinical trial (RCT) comparing the efficacy of carotid
artery stenting (CAS) to carotid endarterectomy (CEA). It is also the largest RCT to assess carotid revascularization in
both symptomatic and asymptomatic patients with carotid artery stenosis. Conventional-risk patients with symptomatic
carotid stenosis (>50% by angiography, >70% by ultrasound) or asymptomatic carotid stenosis (>60% by angiography,
>70% by ultrasound) were randomized to both treatment arms in a 1:1 ratio. Eligibility criteria for CREST were similar
to those of the previous NINDS-sponsored CEA RCTs. The investigational devices used in the CAS arm of the study are
the RX Acculink stent and the RX Accunet embolic protection system, (Abbott Vascular, Santa Clara, Calif). The primary
aim is to contrast the efficacy of CAS versus CEA in preventing stroke, myocardial infarction, and all-cause mortality
during a 30-day peri-procedural period, and ipsilateral stroke over the follow-up period (extending up to four years). The
secondary aims are to contrast the efficacy of CAS and CEA inmen and women, the restenosis rates of the two procedures,
health-related quality of life, and cost effectiveness of CAS and CEA. The conclusion of enrollment in CREST marks the
end of a long recruitment period from 117 community and academic hospital centers across the United States and
Canada. Each surgeon and interventionalist underwent a rigorous credentialing process that included performance-
assessment of prior CEA and CAS procedures. Credentialing of interventionalists also included a review of additional
CAS procedures enrolled into a CREST lead-in phase prior to entering patients into the randomized trial; 1564 patients
were enrolled in the lead-in, the final pathway for the largest credentialing effort to date for any clinical trial. CREST will
provide long-term follow-up after carotid revascularization based on systematic ultrasonographic and neurologic
surveillance, and on quality of life and cost-effectiveness comparisons between CAS and CEA in the setting of a RCT. We
present a brief description of the CREST protocol, impediments that were overcome during the trial, salient results from
the lead-in phase of the trial, a summary of enrollment activities and characteristics of the final cohort, and a timeline for
anticipated results from the randomized phase. ( J Vasc Surg 2009;50:1224-31.)The Carotid Revascularization Endarterectomy vs.
Stenting Trial (CREST), funded by the National Institute
of Neurological Disorders and Stroke (NINDS), is a ran-
domized clinical trial (RCT) comparing the efficacy of
carotid artery stenting (CAS) versus carotid endarterec-
tomy (CEA) in conventional-risk patients with extracranial
From the Division of Vascular Surgery, University of Maryland Medical
Center,a the CREST Administrative Center, University of Medicine and
Dentistry New Jersey-New Jersey Medical School,b and the Department
of Neurology, Mayo Clinic.c
Supported by National Institute of Neurological Disorders and Stroke-
National Institutes of Health (NINDS-NIH) RO1 NS 038384. Addi-
tional funding was provided by Abbott Vascular.
Competition of interest: none.
Reprint requests: Thomas G. Brott, MD, Mayo Clinic, Griffin Building, 3rd
Floor, 4500 San Pablo Rd., Jacksonville, FL 32224 (e-mail: brott.
thomas@mayo.edu).
0741-5214/$36.00
Copyright © 2009 by the Society for Vascular Surgery.
doi:10.1016/j.jvs.2009.09.003
1224carotid artery stenosis. Recent randomized trials have not
definitively resolved whether the efficacy of CAS and CEA
are different.1-5 CREST is the largest study of its kind and is
adequately powered to detect clinically significant differ-
ences between the two procedures. It is the only study to
include both symptomatic and asymptomatic patients in
the same trial. Since the objective is to compare high quality
CEA with high quality CAS, appropriate credentialing was
performed for both groups of investigators, and the study
incorporated accommodation for the learning curve asso-
ciated with the new procedure. This resulted in one of the
largest and most comprehensive lead-in processes ever per-
formed prior to randomization. Finally, carotid ultrasound,
cerebral angiography, and electrocardiography assessments
were reviewed by their respective core laboratories and all
potential endpoints were adjudicated.
The trial is therefore being conducted in the most
optimal conditions achievable for a study of this magnitude
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after the accrual of 1,564 patients in the CREST lead-in
phase. The randomized trial successfully completed enroll-
ment of its target cohort of 2,522 patients from 117
community and academic centers in North America on July
18, 2008. The protocol was approved by the Institutional
Review Boards at participating sites and participants pro-
vided signed informed consent. This has been one of the
most widely anticipated trials among physicians involved in
the treatment of carotid disease, and the lead-in phase has
already contributed important information regarding the
management of carotid stenosis. This brief update reviews
the available data from other trials comparing CAS and
CEA, the design and some of the achievements of CREST,
important conclusions drawn from the lead-in phase, char-
acteristics of the final cohort, and a projected timeline of
future results.
RANDOMIZED TRIALS COMPARING
CAS AND CEA
Published data from recent randomized studies com-
paring CEA and CAS have not been able to provide defin-
itive results. Although CAS has been recommended in
specialized subsets of patients6,7 such as restenosis after
CEA, radiation-induced carotid stenosis, anatomically high
lesions, and in higher-risk patients, the appropriateness of
its use in conventional-risk patients remains an unresolved
matter. The first published multi-center trial, the Carotid
And Vertebral Artery Transluminal Angioplasty Study
(CAVATAS),8 recruited 504 patients. At enrollment 90%
were symptomatic; 253 were randomized to surgical treat-
ment; and 251 underwent endovascular therapy. The com-
bined stroke and death rate at 30 days post-procedure was
9.9% for CEA and 10% for endovascular treatment, and
death or disabling strokes were observed in 5.9% of CEA
patients and 6.4% of endovascular patients. However, these
results are not pertinent today because only 55 of the 251
patients in the endovascular group were treated with a
stent, and an embolic protection device (EPD) was not
used. The CAVATAS investigators have recently published
results based on the long-term follow-up of the same
cohort of 504 patients.9 The eight-year incidence for ipsi-
lateral non-perioperative stroke in the endovascular versus
surgical groups was not significantly different (11.3% vs.
8.6%, hazard ratio [HR] 1.22, 95% confidence interval [CI]
0.59-2.54). In a second report, the authors have compared
the long-term restenosis rates in 413 patients from the
original randomized cohort in whom follow-up informa-
tion was available (200 had endovascular, and 213 received
surgical treatment).10 They found that severe carotid reste-
nosis (70%) or occlusion occurred significantly more
often in patients in the endovascular versus the endarterec-
tomy group over five years (30.7% vs. 10.5%, HR 3.17, 95%
CI 1.89-5.32; P  .0001). Of note, patients in the endo-
vascular arm treated with a stent (n  50) had a lower
restenosis rate versus those treated with angioplasty alone
(16.6% vs. 36.2%, HR 0.43, 0.19-0.97; P  .04). There-
fore, the results may not be entirely generalizable to currentclinical practice that incorporates mandatory stenting.
Since duplex velocity criteria utilized to assess stented pa-
tients was the same as that for native carotid arteries, the
authors cautioned that the restenosis rates may have been
over-estimated in that cohort. These results underline the
need for an adequately powered study comparing the re-
sults of CEA with endovascular therapy using currently
established therapeutic protocols.
The Stenting and Angioplasty with Protection in
Patients at High Risk for Endarterectomy (SAPPHIRE)
trial1,2 was a multi-center clinical trial that randomized 334
patients to CAS or CEA. A total of 68% of the patients were
asymptomatic with stenoses 80% and 32% were symp-
tomatic with stenoses 50%. Participants were considered
high risk for CEA if they were over age 80 years or had
clinically significant heart disease, severe pulmonary dis-
ease, contralateral carotid occlusion or laryngeal nerve
palsy, prior radical neck surgery or radiotherapy, and post-
CEA restenosis. The primary endpoint was a composite of
stroke, death, or myocardial infarction (MI) within 30 days
of the procedure and ipsilateral stroke or death from 31
days to one year post-procedure, which occurred in 12.2%
of the CAS group and 20.1% of the CEA group. The two
procedures were not significantly different (P  .053) and
CAS was therefore deemed non-inferior to CEA. Of con-
cern was the relatively high 30-day composite stroke and
death rate for both procedures, which raised concerns
regarding the expertise of operators in both arms of the
study, patient selection, and whether medical therapy
would have been superior in this high-risk group.
The Endarterectomy vs. Angioplasty in Patients with
Symptomatic Severe Carotid Stenosis trial (EVA-3S)3 was
limited to symptomatic patients with 60% to 99% stenosis.
A total of 262 participants were randomized to endarterec-
tomy and 265 were randomized to stenting. The 30-day
combined stroke and death rate was higher in the CAS
group at 9.6% compared with 3.9% for CEA. The results of
this study have been criticized because of the potential
inexperience of stent operators. Furthermore, 8.1% of the
stenting procedures were performed without an embolic
protection device, and significantly fewer adverse events
occurred in those who had the stenting with embolic
protection.
The Stent-Protected Angioplasty vs. Carotid Endar-
terectomy (SPACE) trial randomized 1,200 symptom-
atic patients with stenoses of 50% to 99% to stenting or
endarterectomy. Stents were used universally, and embolic
protection devices were used in 26% of the patients. The
30-day stroke or death rates were similar, 6.3% vs. 6.8%
(CEA vs. CAS),5 while the two-year stroke plus 30-day
stroke and death rates were also similar 8.8 % vs. 9.5% (CEA
vs. CAS).4 As an inferiority trial, however, randomization
of patients was stopped because CAS was not proven to be
non-inferior to CEA and possibly would not have been
proven according to the trial’s authors, even with the
recruitment of twice the sample size of 1,200 patients.
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In this randomized trial (CREST-randomized), con-
ventional-risk patients with symptomatic carotid stenosis
(50% by angiography, 70% by ultrasound, or 70% by
CTA/MRA if ultrasound is 50%-69%) or asymptomatic
carotid stenosis (60% by angiography, 70% by ultra-
sound, or80% by CTA/MRA if ultrasound is 50%-69%)
were randomized to CAS or CEA in a 1:1 ratio. Eligibility
criteria for CREST were similar to those of the previous
National Institutes of Health (NIH)-sponsored CEA
RCTs, the North American Symptomatic Carotid Endar-
terectomy Trial (NASCET),11,12 and the Asymptomatic
Carotid Atherosclerosis Study (ACAS).13 The CREST pro-
tocol has 90% power to detect an annual absolute difference
of 1.2% in the primary endpoints between CAS and CEA.
Depending on the event rate, CREST also has 80% power
to detect a difference for symptomatic and asymptomatic
patients separately. The investigational devices used in the
CAS arm of the study are the RX Acculink stent and the RX
Accunet embolic protection system (Fig 1), manufactured
by Abbott Vascular, Santa Clara Calif.
The primary aim in CREST is to compare the efficacy of
CAS vs. CEA in preventing stroke, MI, and all-cause mor-
tality during a 30-day peri-procedural period, and ipsilat-
eral stroke over the follow-up period (extending up to four
years). Secondary aims are to: 1) describe the differential
efficacy of CAS and CEA in men and women; 2) contrast
Fig 1. (A) The RX Acculink stent. (B) The RX Accunet embolic
protection system.30-day peri-procedural and post-procedural morbidity andmortality; 3) contrast the restenosis rates of the two proce-
dures; 4) evaluate differences in health-related quality of life
and cost effectiveness; and 5) identify subgroups of partic-
ipants at differential risk for procedural morbidity and
mortality after CAS and CEA.
Prior to participating in the CREST randomized phase,
each interventionalist was required to participate in the
CREST lead-in credentialing phase. Interventional exper-
tise could thus be developed and documented, and learning
curve effects could be minimized. In the lead-in, patients
with symptomatic or asymptomatic high-grade carotid ste-
nosis that had conventional or high risk (as determined by
the presence of medical co-morbidities, cervical radiation/
surgery, high anatomic location, contralateral occlusion, or
post CEA restenosis) were enrolled to undergo CAS by
potential interventionalists. The same RX Acculink/RX
Accunet devices approved for the randomized trial were
used for the purposes of credentialing. Outcomes assessed
were 30-day stroke, MI and death, and one-year ipsilateral
stroke. A multidisciplinary Interventional Management
Committee reviewed the outcomes and credentialed pro-
spective interventionalists. Only then could they participate
in the randomized phase. Analysis of the data from the
1,564 CAS patients enrolled in the lead-in has yielded
important results; some are summarized below.
All endpoints for the lead-in were reviewed by a Clinical
Events Committee. For the randomized phase, all end-
points are evaluated by either the Stroke or the Myocardial
Infarction Adjudication Committees, and members of
these committees are blinded to the assigned treatment.
Recurrent or new ischemic stroke was defined as an acute
neurological ischemic event of at least 24 hours duration
with focal signs and symptoms. One or both of the follow-
ing could be used as confirmatory evidence but not neces-
sary for the designation of stroke: a one-point increase on
the NIH Stroke Scale or an appropriate new or extended
abnormality seen on computed tomography (CT) or mag-
netic resonance imaging (MRI). Review for potential
stroke was triggered by a positive transient ischemic attack/
stroke questionnaire and NIH Stroke Scale as performed
preoperatively and during follow-up by a study neurologist.
Postoperative or procedural MI is determined by electro-
cardiography, enzyme abnormalities, or clinical presenta-
tion of MI. Post-procedural restenosis is determined by
duplex ultrasonography with review by a core laboratory.
Quality of Life and economic analyses were also carried out
by a core laboratory.
OVERCOMING OBSTACLES IN CREST
CREST was funded as a multi-center RCT on January
15, 1999. The trial could not commence because despite
previous assurances of coverage for CREST, Health Care
Financing Administration (HCFA; currently Centers for
Medicare and Medicaid Services [CMS]), denied reim-
bursement for CAS. In June, 2000, President Clinton
issued an Executive Order directing HCFA to reimburse
Medicare participants in NIH clinical trials. More than a
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2001.
Around that time, cerebral EPDs began to gain wide
acceptance among interventionalists. They expressed a re-
luctance to perform CAS without the option to use a
protection device. Embolic protection was introduced into
CREST, necessitating protocol amendments and new In-
stitutional Review Board approvals. The FDA approved the
incorporation of the ACCUNET device into CREST in
August 2001. It is at this point that recruitment to CREST
commenced and continued to increase from four to 20-40
subjects per month.
In February 2002, a product malfunction in the recov-
ery catheter of ACCUNET occurred in a non-CREST case.
While no adverse event occurred and the device was re-
trieved successfully, recruitment to CREST was halted for
product investigation and recall. Once appropriate modifi-
cations to the recovery catheter and protocol were ap-
proved by the FDA, NIH, and IRBs, enrollment was re-
sumed in June 2002.
Finally, while these delays were occurring, several
competing FDA-approved trials began to affect random-
ization to CREST. While the inclusion/exclusion crite-
ria of these industry-funded trials did not technically
overlap, they had registry components and features that led
to practical study overlap and enrollment competition (eg,
SAPPHIRE, ARCHeR, and CAPTURE).
CREST CONCLUDES ENROLLMENT IN THE
LEAD-IN PHASE
In a trial in which two technical procedures are being
compared with regard to immediate and long-term results,
it was of paramount importance that the expertise of inves-
tigators be established prior to participation. Since the
objective was to compare high quality CEA with high
quality CAS, appropriate credentialing had to be performed
for both groups of investigators. This would ensure that the
outcome of the two procedures was compared under ideal
circumstances, and would not be influenced by varied
technical expertise in either group. The process of creden-
tialing surgeons performing CEA was well-established
through two prior NIH-sponsored clinical trials.11,13 A
similar rigorous credentialing process for surgeons was
successfully implemented in CREST and was described
previously.14
The credentialing process for interventionalists in-
volved a thorough evaluation of clinical facilities at a poten-
tial site by the Site Selection Committee, and an assessment
of the clinical and technical expertise of the site’s interven-
tionalists by the Interventional Management Committee
(IMC) as outlined above.15 The IMC consisted of a multi-
disciplinary group of physicians (from neurology, vascular
surgery, interventional cardiology, interventional radiol-
ogy, and neurosurgery). Credentialing of the intervention-
alists involved a unique two-step process. First, potential
interventionalists were evaluated by the IMCbased on their
prior experience with CAS. Their patients’ evaluation, pro-
cedure reports, and outcomes were scrutinized. If deficien-cies in knowledge-base or technical skills were identified
and/or a high complication rate was noted, then those
interventionalists were excluded from participation. The
interventionalists who were deemed to have adequate prior
experience were then allowed to enter the second step of
the credentialing process consisting of the lead-in phase.
The lead-in phase was built into the study and was funded
by the NIH. The approved interventionalists underwent
training with the study devices, which included use of
animal models, and performed up to 20 lead-in CAS cases.
Final IMC approval to enter the randomization phase of
CREST was based on safety and technical proficiency dem-
onstrated during the lead-in phase of the trial. Once the
randomized phase of the trial was completed, the creden-
tialing process was concluded with 1,564 patients included
in the CREST lead-in phase.
FINDINGS FROM THE LEAD-IN PHASE
The CREST protocol included one of the largest
credentialing efforts ever undertaken prior to initiating
participation in a formal randomized trial. This resulted
in the collection of demographic, procedural, and rigor-
ous one-year follow-up of the lead-in cohort. The anal-
ysis of this experience, which we briefly summarize be-
low, has been presented in abstracts and manuscripts,
and will be the subject of more upcoming manuscripts.
A rigorous credentialing process is feasible prior to
randomization in a large RCT of CEA and CAS.15 The
IMC was fairly stringent in its review, insisting that the
majority of operators demonstrate their expertise by per-
forming from five to 20 CAS procedures in the closely-
monitored lead-in phase. A minority were allowed to initi-
ate randomization directly, based upon their high volume
of CAS procedures, familiarity with the CREST study de-
vices, and good procedural outcomes. The specialties from
which interventionalists were derived are shown in Fig 2
and reflect the varied specialties involved in performing
CAS procedures in the community.
Lead-in phase outcomes. The rigorous selection pro-
cess and monitoring of outcomes in the lead-in phase was
associated with an overall 30-day stroke and death rate of
Fig 2. The distribution of interventionalists by medical specialty
who were credentialed for the randomized phase of CREST.4.4%  0.6%,16 which compares favorably with the sug-
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Association17 guidelines for carotid revascularization. De-
tailed results of symptomatic and asymptomatic patients are
presented in Table I.
Age-related outcomes. The lead-in phase has been
instrumental in highlighting subsets of patients that may be
particularly high-risk for CAS. In the process, it has helped
clinicians to improve patient selection and therefore, out-
comes after CAS. One of the earliest trends observed and
reported from the lead-in phase was the relatively high
morbidity obtained by CAS performed on elderly pa-
tients.18 The results were counter to the expectations of
some that the minimally invasive procedure would offer less
cardiac morbidity in this cohort. The association of stroke
with age is consistent and the adverse events were observed
to rise with each decade (Fig 3). While there was not a
surgical comparison in the lead-in phase, the safety concern
specific to CAS was confirmed in the SPACE trial, where
the 30-day rates of stroke and death for stenting were
significantly higher with advancing age, being 11.1% for
stenting and 7.5% for endarterectomy in those aged 75
years or older. These results have instilled a cautionary note
for CAS in the elderly. Several mechanisms are potential
mediators of this effect, including carotid arterial tortuosity
and calcification, as well as increased aortic arch angulation
and atheromatous involvement associated with aging. It
remains to be seen how age will interact with the outcomes
Table I. Thirty-day stroke and/or death after carotid
artery stenting in the CREST lead-in phase
Symptomatic Asymptomatic
CREST lead-in 5.8  1.2 (n  414) 3.8  0.6 (n  1150)
NASCET 6.7
ECST 7.5
ACAS 2.3
ACST 3.1
EVA3S 11.7
SPACE 6.8
ACAS, Asymptomatic Carotid Atherosclerosis Study;ACST, Asymptomatic
Carotid Surgery Trial; CREST, Carotid Revascularization Endarterectomy
versus Stenting Trial; ECST, European Carotid Surgery Trial; EVA-3S,
Angioplasty in Patients with Symptomatic Severe Carotid Stenosis;
NASCET, North American Symptomatic Carotid Endarterectomy Trial;
SPACE, Stent-Supported Percutaneous Angioplasty of the Carotid Artery
versus Endarterectomy.
Fig 3. The 30-day rate of any stroke or death by age cohorts.between CEA and CAS in the randomized cohort ofCREST patients since CEA may cause increased adverse
events in the elderly from anesthetic stress.
Factors that may increase the risk of periprocedural
complications associated with CAS include anatomic con-
siderations such as a type III aortic arch, severe aortic or
carotid calcification, arterial tortuosity, high-grade stenosis,
and intra-arterial thrombus. The potential relationship of
these factors to clinical outcomes in the lead-in cohort is
being analyzed. These data emphasize the importance of
appropriate lesion sizing and accuracy of stent deployment
during carotid stenting.
Hemodynamic events and outcome. Several CAS
procedures have been associated with hemodynamic insta-
bility during or after the stenting. Since the long-term
significance of these events was not well-defined, the
CREST lead-in data were evaluated to determine the risk of
stroke or death associated with hemodynamic and hemor-
rhagic events occurring within seven days of CAS.19 Hem-
orrhagic complications included groin or retroperitoneal
bleeds and excluded cerebral hemorrhage. Hemodynamic
events were defined as having hypotension. There were 21
patients with either a bleed or hematoma, and their 30-day
stroke and death rate was 19.6% vs. 4.3% in those without.
Peri-procedural hypotension occurred in 71 patients; the
event rate was 4.1% for those without hypotension and
11.4% for those with hypotension (P  .004). These data
emphasize the importance of careful technique, hemody-
namic monitoring, and aggressive management of hemo-
dynamic events during CAS. While hemodynamic events
are known to occur with both procedures, the CREST
randomized study will be able to report whether they are
significantly different from each other.
Restenosis after CAS. The incidence of luminal nar-
rowing of the internal carotid artery as measured by Duplex
ultrasound (DUS) following CAS has been controversial.
There is concern that altered compliance as a result of the
stent may result in alterations in the recorded velocities that
may overestimate the actual degree of re-stenosis after
CAS.20,21 The CREST investigators therefore analyzed
the restenosis rates observed at one year of follow-up in the
CREST lead-in cohort using the one-month DUS as the
baseline.22 This eliminated potential stent-generated arti-
facts in the assessment of re-stenosis. Thirteen percent of
the lead-in patients demonstrated in-stent restenosis as
determined by a 2 SD increase in their peak systolic
velocities from the one-month to one-year DUS. Only
1.2% of patients however, required repeat revascularization
by one year of follow-up. The SPACE trial has subsequently
reported that recurrent stenosis of 70% by duplex oc-
curred in 4.6% of patients undergoing CEA and 10.7% of
those undergoing CAS (P .0009).4 The SAPPHIRE study
had noted a restenosis 50% rate of 19% at one year.1 The
lead-in results highlight the importance of this endpoint,
since early periprocedural benefit with one procedure may
be offset by a higher recurrence and re-intervention rate
associated with that procedure in the long-term. The re-
sults of the CREST randomized study are awaited, which is
e rand
JOURNAL OF VASCULAR SURGERY
Volume 50, Number 5 Lal and Brott 1229adequately powered to provide evidence comparing the
restenosis rates associated with CAS vs. CEA.
Differential effects by gender. In the Asymptomatic
Carotid Atherosclerosis Study (ACAS),13 men with asymp-
tomatic stenosis undergoing CEA had a 66% relative risk
reduction in adverse events over five years but only a 17%
reduction occurred for women. In the North American
Symptomatic Carotid Endarterectomy Trial (NASCET),
no differential gender effects were seen among patients
with 70% stenosis.11 However, men with 50%-69% ste-
nosis had greater benefit after CEA than women.12 In
EVA-3S, the excess risk associated with stenting on univar-
iate analysis was greater for men (P  .03),3 while in
Fig 4. The location of th
Fig 5. The randomization into CREST by symptomatic status
over time.SPACE there were no differences noted after CAS betweengenders (n  338 women).4 The causes for a differential
efficacy between genders are not well understood, but none
of the previous randomized trials anticipated a differential
gender effect and they were therefore underpowered to
address the question. Based on these results, CREST was
designed with plans to evaluate the possibility of a dif-
ferential gender effect. Women comprised 37% of the
CREST lead-in cohort23 and were no different from men
based on age, symptomatic status, or characteristics of
the internal carotid artery. The 30-day stroke and death
rate for women was 4.5% (26/579) compared with 4.2%
(41/985) in men. The difference in stroke and death rate
was not significant nor were there any significant differ-
ences by gender after adjustment for age, anatomic fea-
tures, or risk factors.
CREST COMPLETES ENROLLMENT IN THE
RANDOMIZED TRIAL
Originally, CREST had FDA approval for only 40
omizing sites in CREST.
Table II. Demographic features of the randomized
cohort of CREST
Demographic features Incidence
Gender (female) 37%
Diabetes 30%
Hypertension 85%
Dyslipidemia 83%
Current smoker 25%
Previous CABG 21%clinical centers to recruit patients, but study leadership
tion
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ment goals in a timely fashion. Maximizing the number of
CREST centers was crucial in overcoming the initial road-
blocks to recruitment faced by the study (Fig 4). Once the
issues related to CMS, FDA, and other logistics were satis-
fied, efforts were concentrated on identifying and activating
qualifying sites, and CREST recruitment increased dramat-
ically from 2004 onwards from under 10 patients per
month to over 50 per month. The average monthly rate of
enrollment between January and June of 2008 was 54.
With an additional 35 patients randomized in July, CREST
enrollment was completed on July 18, 2008 (Fig 5).
While the randomized results will not be available for
several months, some general information is presented
here. The total patients randomized in CREST were 2,522
of which 53% (n  1326) were symptomatic patients and
47% (n  1196) were asymptomatic. As of July 18, 2008,
117 centers had enrolled at least one CREST participant.
Enrollment of women was 37% of total patient randomiza-
tions and minority recruitment was 9.3%. The distribution
of general risk factors among those recruited mirrors that of
a typical population of patients with atherosclerotic occlu-
sive disease, with a notably high incidence of hyperlipid-
emia and coronary heart disease (Table II). The mean age
of this cohort is 69.1 years. The adverse event rates for the
cohort are not available as yet. However, it is clear that
adverse events in either group of patients (CAS or CEA)
were not high enough to warrant a premature closure or
advisory from the independent CREST Data Safety and
Monitoring Board.
Exceptional efforts are required to accomplish and
complete a multi-center RCT. The success of CREST rests
primarily with the enrolling clinical centers. In addition to
their accomplishments, a large coordinated effort by
NINDS, the CREST Administrative Center, the Recruit-
Fig 6. (A) Important milestones and challenges leadin
(B) The recent and upcoming milestones in the culminament Center, the Statistical and Data Management Center,the core laboratories, FDA, and CMS has gone into the
study. The medical community is eager for results. A time-
line of the prior and projected activities related to CREST is
presented in Fig 6. It is anticipated that CREST will be
reporting its stated outcomes by early 2010 with conse-
quent major practice-changing implications regarding the
care of patients with carotid disease, both symptomatic and
asymptomatic.
We express our thanks to the CREST Publications and
Presentations Committee for their review of the manu-
script.
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